BOSTON--(BUSINESS WIRE)--Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc.

波士顿-（商业线）-专业生命科学咨询和投资银行公司Outcome Capital今天宣布，电子注册系统公司（ERS）是癌症注册解决方案和合规与信息服务的领先提供商，已被Health Catalyst，Inc。收购。

(“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with more than 50 health systems clients covering 110 million patients. Outcome Capital served as the exclusive strategic and financial advisor to ERS..

（“Health Catalyst”，纳斯达克股票代码：HCAT）是一家医疗技术和数据分析公司，拥有超过50家医疗系统客户，覆盖1.1亿患者。成果资本是ERS的独家战略和财务顾问。。

With the growing cancer burden of an estimated $200 billion annual spend in the U.S. and more than 100 distinct cancer types, further progress in the cancer treatment space will require automated data exchange from numerous sources enabling seamless integration of multiple data streams into a single, accessible patient file.

随着美国每年花费2000亿美元的癌症负担日益增加以及100多种不同的癌症类型，癌症治疗领域的进一步发展将需要来自众多来源的自动数据交换，从而能够将多个数据流无缝集成到一个可访问的患者文件中。

ERS, a profitable, B2B SaaS company in the cancer data and analytics segment, has distinguished itself in recent years from its competition with more than 750 cancer center partnerships and longitudinal data covering more than 10 million patient records, and moving fully to a cloud-based offering and collaborating with best-in-class technology partners who provide innovations from Natural Language Processing (NLP), patient navigation and precision medicine to multi-disciplinary care platforms.

ERS是癌症数据和分析领域有利可图的B2B SaaS公司，近年来与其与750多个癌症中心合作伙伴的竞争以及涵盖1000多万患者记录的纵向数据脱颖而出，并充分转向基于云的提供和与一流的技术合作伙伴合作，这些合作伙伴提供从自然语言处理（NLP），患者导航和精准医学到多学科护理平台的创新。

ERS’ cancer registry software utilizes 785 individual data fields that are tracked in a health system’s or cancer center’s efforts to measure and improve treatment effectiveness and long-term patient outcomes..

ERS的癌症登记软件利用785个单独的数据字段，这些数据字段在卫生系统或癌症中心的努力中进行跟踪，以衡量和改善治疗效果和长期患者结果。。

“From my first meeting with Rohit Nayak, CEO of ERS, I could envision numerous potential acquirers, as robust, curated, longitudinal patient data is still king, whether in healthcare or the life sciences,” Karl Hess, managing director at Outcome Capital commented. “With Health Catalyst, it was clear that the overall similar strategic approaches, numerous synergies and well-aligned corporate cultures were a perfect match.

“从我与ERS首席执行官Rohit Nayak的第一次会议开始，我可以设想许多潜在的收购者，因为无论是在医疗保健还是生命科学领域，强大，精心策划的纵向患者数据仍然是国王，”成果资本总经理Karl Hess评论说。“有了健康催化剂，很明显，整体相似的战略方法，众多协同作用和良好的企业文化是完美的匹配。

The culmination of this process and the transaction represent a substantial ‘win’ for both parties, as well as their many shared (and net new) health system clients, who will undoubtedly benefit from the additional capabilities ERS adds to Health Catalyst’s already full quiver of healthcare data and analytics solutions.”.

这一过程和交易的高潮为双方以及他们的许多共享（和净新）卫生系统客户带来了实质性的“胜利”，他们无疑将受益于ERS增加健康催化剂已经完全颤动的额外功能。医疗数据和分析解决方案“。

Health Catalyst analytics applications platform and companion professional services together address the most pressing concerns of health care organizations, including managing population health; gaining a comprehensive view of the true cost of care; empowering executive decision support with a dashboard view of enterprise-wide performance; benchmarking and prioritizing improvement opportunities; and monitoring, detecting, predicting and preventing threats to patient safety, before harm can occur..

健康催化剂分析应用平台和同伴专业服务共同解决卫生保健组织最紧迫的问题，包括管理人口健康；全面了解护理的真实成本；通过企业范围绩效的仪表板视图授权执行决策支持；对改进机会进行基准测试和优先排序；并在可能发生伤害之前监测，检测，预测和预防对患者安全的威胁。。

“Outcome Capital was a true partner and collaborator starting from the evaluation and sourcing phase. Their teamwork and attention to detail was perfectly accompanied by their knowledge and expertise with the industry segment,” said Rohit. “Furthermore, their diligence prep rigor was extremely useful once we got to the post term-sheet/closing phase of the transaction.

Rohit说：“成果资本是从评估和采购阶段开始的真正合作伙伴和合作者，他们的团队合作和对细节的关注完全伴随着他们在行业领域的知识和专业知识。”。“此外，一旦我们进入交易的后期表/结束阶段，他们的勤奋准备非常有用。

As a small business owner, I know I could not have survived the arduous legal and closing phase of this transaction without their help.”.

作为一家小企业主，我知道如果没有他们的帮助，我不可能在这项交易的艰苦法律和结束阶段幸存下来。”。

About Outcome Capital

关于成果资本

Outcome Capital is a unique and highly specialized life sciences advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering, financing and strategic advisory. The firm uses its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and strategic markets and implementing the best path for success.

成果资本是一家独特且高度专业化的生命科学咨询和投资银行公司，为创新公司提供增值，市场一致的兼并收购，合作，融资和战略咨询方法。该公司通过协助管理团队及其董事会导航金融和战略市场并实施最佳成功途径，采用经过验证的“战略主导执行”方法来提高价值。

Outcome Capital’s strength stems from its multi-disciplinary team consisting of industry veterans who draw from their wide range of scientific, operational, strategic, and transactional expertise across the value chain, and broad industry network and relationships. Comprised of former CEOs, PhD/MD level scientists and clinicians, business development executives, and experienced commercialization experts, our team is driven to propel innovation from bench to bedside.

成果资本的优势源于其多学科团队，该团队由行业退伍军人组成，他们从价值链中广泛的科学，运营，战略和交易专业知识以及广泛的行业网络和关系中汲取经验。由前首席执行官，博士/医学博士级科学家和临床医生，业务发展高管以及经验丰富的商业化专家组成，我们的团队致力于推动从实验室到床边的创新。

Outcome Capital, Member FINRA/SIPC. please visit http://www.outcomecapital.com..

成果资本，FINRA/SIPC成员。请访问http://www.outcomecapital.com..

About ERS, Inc.

关于ERS，Inc。

With CRStar, the industry’s first true cloud-based offering with innovative case-finding, abstracting and informatics capabilities, ERS, a Health Catalyst Company, empowers cancer centers to achieve their full potential by meeting and exceeding increasing regulatory, accreditation and quality reporting requirements while providing insights for enhancing cancer program management.

凭借CRStar，该行业首款真正的基于云的创新案例发现，抽象和信息功能，ERS是一家健康催化剂公司，通过满足和超越不断增长的监管，认证和质量报告要求，使癌症中心能够充分发挥其潜力，同时提供见解加强癌症项目管理。

More than a cancer registry and accreditation solution, many of our customers leverage CRStar as a knowledge center of actionable information to help guide key resource management, planning and program growth decisions with an emphasis on quality and research. For more information, please visit www.mycrstar.com..

除了癌症登记和认证解决方案之外，我们的许多客户利用CRStar作为可操作信息的知识中心，帮助指导关键资源管理，规划和计划增长决策，重点是质量和研究。欲了解更多信息，请访问www.mycrstar.com。。

About Health Catalyst

关于健康催化剂

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements.

Health Catalyst是医疗保健组织的数据和分析技术及服务的领先供应商，致力于成为大规模，可衡量，数据知情的医疗保健改进的催化剂。其客户利用基于云的数据平台，该平台由来自1亿多患者记录的数据提供支持，涵盖数万亿个事实以及其分析软件和专业服务专业知识，以做出数据明智的决策并实现可衡量的临床，财务和运营改进。

Health Catalyst envisions a future in which all healthcare decisions are data informed. For more information, please visit http://www.healthcatalyst.com..

健康催化剂设想了一个未来，在这个未来中，所有的医疗决策都是数据知情的。欲了解更多信息，请访问http://www.healthcatalyst.com..